Deals

J&J to Acquire Intra-Cellular for About $14.6 Billion

Health-care dealmaking picking up again after 2024 slump
Intra-Cellular develops treatments for mental health disorders

J&J to Buy Intra-Cellular for About $14 Billion

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Michelle F Davis and Dinesh Nair

January 12, 2025 at 9:20 PM UTC

Updated on

January 13, 2025 at 2:33 PM UTC

This article is for subscribers only.

Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system disorders, for about $14.6 billion.

J&J will pay $132 a share, the company said in a statement. That’s 39% above the closing price on Friday. Bloomberg earlier reported a deal was in the works.